Czech Republic - Immunosuppressants - Framework agreement containing ofatumumab 2026 - joint procurement

This Czech joint procurement concerns recurring supplies of medicinal products containing the active substance ofatumumab, an immunosuppressant. The products must meet the requirements of the Czech State Institute for Drug Control (SÚKL). The contract covers repeated deliveries of these medicines, referenced to 2026 in the title, and is organised as a joint purchase on behalf of the participating contracting entities. No specific quantities, delivery schedules or lots are described beyond the recurring nature of the supply of ofatumumab-containing medicinal products. The notice therefore covers an ongoing supply arrangement for this single active substance rather than a one-off purchase, with compliance with SÚKL requirements as the stated quality benchmark for the products procured.

Description

4 open tenders right now

• Czech Republic - Systemic hormonal preparations except sex hormones - medicines containing relugolix 2026 - joint purchase 14 Oct 2026 · 20 days left
• Czech Republic - Antineoplastics - Framework agreement for ramucirumab 2026 - joint purchase 23 Oct 2026 · 29 days left
• Czech Republic - Antivirals for systemic use - medicinal products containing molnupiravir 2026 - joint procurement 29 Oct 2026 · 35 days left

This buyer has no award history in this sector yet. Usual winners, Medical equipment & pharmaceuticals - Czechia

Based on 2953 awards with a linked company profile over the last 2 years.

Market context

Avg. open tender · Medical equipment & pharmaceuticals

€10,142,739

9,882 open across Europe right now 51% above sector average

Buyer track record on Aperlena

10 notices tracked · 0 awarded